Open AccessApolipoprotein A5 in health and disease
Author(s) -
Jaroslav A. Hubacek,
Adamkova Adamkova,
Michal Vráblík,
Michaela Kadlecová,
Josef Zicha,
Jaroslav Kuneš,
Jan Piťha,
Pavel Suchánek,
R. Poledne
Publication year - 2009
Publication title -
physiological research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 70
eISSN - 1802-9973
pISSN - 0862-8408
DOI - 10.33549/physiolres.931911
Subject(s) - apolipoprotein b , medicine , endocrinology , population , cholesterol , allele , triglyceride , apolipoprotein e , transgene , lipoprotein , genetically modified mouse , biology , gene , disease , genetics , environmental health
High plasma levels of triglycerides (TG) are an independent riskfactor in the development of cardiovascular disease, with about50 % of the final levels being determined genetically.Apolipoprotein A5 (APOA5) is the last discovered member of theapolipoprotein APOA1/C3/A4 gene cluster, found by comparativesequencing analysis. The importance of APOA5 gene fordetermination of plasma triglyceride levels has been suggestedafter development of transgenic and knock-out mice (transgenicmice displayed significantly reduced TG, whereas knock-out micehad high TG). In Czech population, alleles C-1131 and Trp19 areassociated with elevated levels of plasma TG and higher risk ofmyocardial infarction development. These alleles also play somerole in nutrigenetics and actigenetics of lifestyle interventionsleading to the plasma cholesterol changes as well as in thepharmacogenetics of statin treatment. On the contrary, APOA5mutations detected in Czech population did not show strict effecton plasma TG levels. Val153 → Met variant exhibit the sexspecific effect of HDL-cholesterol levels. The suggested roles ofAPOA5 variants in determination of the plasma remnant particles,plasma concentrations of C-reactive protein or someanthropometrical parameters were excluded.